Finding Treatment Synergy in CLL: Expert Consults on Advances with Targeted and Cellular Therapy

Are you prepared to achieve therapeutic synergy in CLL and leverage the potency of targeted platforms along with emerging cellular therapy options? Find out by watching this “Clinical Consults” event recorded at the 2023 Tandem Meetings, where experts presenting the latest practice-changing evidence provide practical take-homes on the upfront and sequential use of covalent and noncovalent BTK and BCL-2 inhibitors, the emergence of potent chemo-sparing combinatorial approaches, the changed role of HCT, and the development of CAR-T cell options in pretreated CLL. Get CME credit and hear how experts are getting better outcomes through treatment synergy, including in challenging and high-risk CLL settings.


This activity is supported through educational grants from AstraZeneca and Bristol- Myers Squibb.


Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, HCT and cellular therapy specialists, HCT nurse specialists, and other healthcare professionals involved in the care of patients with CLL.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize the safety and efficacy evidence and practice guidelines supporting the use of novel BTK and BCL-2 inhibitors, and CAR-T cellular therapy, including as part of novel combinations and sequential approaches, across the spectrum of CLL
  • Integrate novel targeted and cellular approaches in conjunction with monitoring strategies for the personalized management of patients with TN and RR CLL
  • Manage the unique spectrum of adverse events associated with the use of novel therapies in the CLL setting
Additional information


Sherry Fisher
Phone Number: 
+1 (414) 805-0689
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.
Course opens: 
Course expires: 
ACCME Accreditation Statement:
The Medical College of Wisconsin is accredited by the Accreditation Council for continuing Medical Education (ACCME) to provide continuing medical education for physicians. 
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
This activity is co-provided with our educational partner, PVI, Peerview Institute.

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.


Please login or register to take this course.